MDI Health, an Israeli medtech startup that offers an AI-powered platform that automates the optimization of personalized medication treatment, raised $20 million in a Series A funding round led by Intel Capital with participation from Maverick Ventures Israel and existing investors. The company has now raised a total of $28 million to date including a $6 million seed round held in 2021.
MDI Health boasts that the firm is equipping clinicians with the technology they need to prevent adverse drug reactions, which are the fourth leading cause of death in the U.S., resulting in an estimated more than 270,000 deaths each year
In recent years Israel has become known as the startup state or Startup Nation. The country has had multi-billion dollar exits for numerous software and security companies. But Startup Nations is also known for its medtech startups. Israel has always been a center for medical research and innovation. Now put that together with its startup culture and you have medtech nation.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Founded in 2019 by Dr. Dorit Nahlieli and Avishai Ben-Tovim. MDI declares that its tech can prevent medication related problems, using data and AI, to create “immense clinical, financial, and social impact in healthcare.”
MDI Health explains that current medication management solutions are largely alert-based, focusing on drug interactions and requiring laborious processes. Whereas, MDI Health’s AI medication management platform is autonomous and hyper-personalized. It analyzes thousands of influencing factors to identify medication-related risks – and provides a recommendation to mitigate such risks – in a matter of minutes instead of hours, driving significant cost savings and improved health outcomes at scale.
The MDI Health solution is powered by AI to enable clinicians to run high quality CMRs (comprehensive medication reviews) at scale. The company says that this can improve patient outcomes, prevent hospitalizations and reduce medication-related issues, which cost $528 billion annually. The MDI technology collects patient medical data, detects patients at risk, identifies and helps prevent potential adverse drug events, and continuously monitors patient health.
MDI can be implemented within health payer programs, at-risk provider programs, and Medicare/Medicaid programs as integrated SaaS or as a complete turnkey solution.
“MDI Health is driven by our mission to help end the preventable suffering of patients caused by an outdated one-size-fits-all approach to medication treatment. The ongoing support and new funding from our investors equips us with the fuel we need to accelerate that mission,” said CEO Ben-Tovim.